Related Experiment Video
Updated: Jun 19, 2026
08:45
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
Transporter pharmacogenetics and statin toxicity.
1Department of Clinical Pharmacology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland. mikko.niemi@helsinki.fi
Clinical Pharmacology and Therapeutics
|November 6, 2009
Summary
Genetic variations in drug transporters significantly impact how the body processes statins, influencing myopathy risk. Understanding these genetic differences allows for personalized statin therapy to improve lipid-lowering treatment.
Area of Science:
- Pharmacogenomics
- Drug Metabolism and Transport
Background:
- Genetic polymorphisms in drug transporters critically affect statin pharmacokinetics.
- Specific variants, like organic anion-transporting polypeptide 1B1 (OATP1B1) and adenosine triphosphate (ATP)-binding cassette G2 (ABCG2) transporter, influence statin absorption and elimination.
- These transporter variations are linked to altered systemic exposure and increased risk of statin-induced myopathy.
Purpose of the Study:
- To elucidate the impact of genetic polymorphisms in key drug transporters on statin pharmacokinetics.
- To highlight how transporter gene variants differentially affect the disposition of various statins.
- To establish a scientific rationale for personalized statin therapy based on genetic profiles.
Main Methods:
- Review of existing literature on genetic polymorphisms in OATP1B1 and ABCG2 transporters.
- Analysis of pharmacokinetic data for various statins in relation to common genetic variants.
- Correlation of transporter activity with clinical outcomes, specifically statin-induced myopathy.
Main Results:
- Common polymorphisms in OATP1B1 reduce hepatic statin uptake, increasing myopathy risk.
- Impaired ABCG2 transporter efflux activity leads to higher systemic statin exposure.
- The impact of these genetic variations on statin pharmacokinetics is statin-specific.
Conclusions:
- Genetic variations in OATP1B1 and ABCG2 transporters significantly influence statin pharmacokinetics and safety.
- Statin-specific effects of genetic polymorphisms necessitate tailored therapeutic strategies.
- Individualizing statin therapy based on genetic transporter profiles offers a rational approach to optimize lipid-lowering treatment and minimize adverse events.
Related Concept Videos
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion, mediated...
A recent model describes pravastatin's hepatobiliary excretion, mediated...
01:27Nonlinear Pharmacokinetics: Role of Transporters
A drug's nonlinear kinetics can be influenced by a diverse range of transporter proteins that serve as crucial players in drug distribution. These transporters, found within cells, can enhance or reduce local drug concentrations by facilitating the influx or efflux of drugs. For instance, the expression of xenobiotic transporters can be influenced by factors such as age and gender, potentially impacting the linearity of drug response.
Polymorphisms occurring in drug transporters can alter...
Polymorphisms occurring in drug transporters can alter...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...